Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says
This article was originally published in PharmAsia News
Executive Summary
Cardiome Pharma will likely be announcing a change in ownership for the U.S. rights to the I.V. version of its cardiovascular drug vernakalant by the end of the first quarter, CEO Doug Janzen told analysts on an earnings call